Entries by admin

Enterprise Therapeutics publishes on medicinal chemistry of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis

/in /by

Paper in the European Journal of Medicinal Chemistry discloses the optimisation process leading to the selection for development of ETD001, an inhaled ENaC blocker with a best-in-class profile ETD001 commenced Phase 2 clinical study in people with cystic fibrosis in July 2024 Brighton, UK, 19 November 2024: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated […]

Enterprise Therapeutics granted ‘rare pediatric disease designation’ in the US for novel cystic fibrosis investigational therapy ETD001

/in /by

ETD001 is a novel, first in class blocker of the epithelial sodium channel (ENaC) aimed at treating people with cystic fibrosis without current effective therapies ETD001 commenced Phase 2 clinical trials in July 2024, expected to complete in 2025 Brighton, UK, 26 September 2024: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery […]

Enterprise Therapeutics appoints Annabella Amatulli as Head of Regulatory Affairs

/in /by

Appointment brings extensive regulatory experience as lead asset ETD001 progresses through Phase 2 clinical trial for treatment of cystic fibrosis Brighton, UK, 11 September 2024: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of those suffering from respiratory disease, today announced the appointment […]

Enterprise Therapeutics Doses First Person with Cystic Fibrosis in Phase 2 Trial for Novel Therapy ETD001

/in /by

Trial aims to deliver clinical proof-of-concept and assess the safety profile of novel long acting ENaC inhibitor ETD001 ETD001, a CFTR mutation agnostic approach to CF, is focussed on providing a novel treatment for members of the CF community that do not benefit from currently available mutation-targeted therapies Brighton, UK, 23 July 2024: Enterprise Therapeutics […]

Enterprise Therapeutics appoints Dr Renu Gupta as Chief Medical Officer and Dr Janet Hammond as Non-Executive Director

/in /by

Appointments bring additional respiratory and late clinical-stage drug development experience as Company commences Phase 2a clinical trial of its lead asset Brighton, UK, 17 June 2024:Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced the appointment […]

Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker

/in /by

Low doses of ETD001 demonstrate exceptionally long duration of action in sheep model of airway mucus clearance Report in Journal of Cystic Fibrosis discloses best-in-class profile of ETD001 ETD001 scheduled to commence Phase 2 clinical study in people with cystic fibrosis in summer 2024 Brighton, UK, 12 June 2024: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical […]

Enterprise Therapeutics appoints Dr Niyati Prasad as Chief Medical Officer

/in /by

Dr Prasad will lead Enterprise’s development strategy to support the continued advancement of the Company’s respiratory programmes through the clinic Brighton, UK, 8 February 2022: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced it has […]

Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001

/in /by

ETD001 is a novel inhaled, long-acting ENaC inhibitor Therapy applicable to all cystic fibrosis patients, independent of genotype Brighton, UK, 14 June 2021: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced it has successfully dosed […]

Enterprise Therapeutics’ First-in-Class TMEM16A potentiator program for treatment of cystic fibrosis and other respiratory diseases acquired by Roche

/in /by

Enterprise’s novel TMEM16A potentiator portfolio includes ETD002, a first in class compound which is currently in Phase 1 TMEM16A potentiation is a novel therapeutic approach applicable to all cystic fibrosis patients, independent of CFTR genotype, and may provide benefit in other respiratory diseases Enterprise’s shareholders received an upfront payment of £75 million Brighton, UK, 07 […]